Geneticist’s age-reversal technology advances to human clinical trials for vision restoration

Geneticist Yuancheng (Ryan) Lu is pioneering age-reversal gene therapies aimed at treating age-related vision loss. Lu’s research, which began during his PhD at Harvard, utilizes a reprogramming technique known as OSK to reset cells to a youthful state without inducing the oncogenic risks associated with traditional methods. His breakthrough, which successfully restored vision in mice with crushed optic nerves, has now transitioned into human clinical trials. The startup Life Biosciences, co-founded by David Sinclair, recently initiated a trial injecting the treatment, ER-100, into a patient with glaucoma. While the field of rejuvenation science faces significant hype and massive venture capital investment, Lu remains focused on the rigorous scientific challenges of refining these therapies. His work represents a significant milestone in regenerative medicine, moving from laboratory success to potential clinical application for patients suffering from degenerative eye conditions.